

1 **Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for**

2 **SARS-CoV-2 by RT-PCR**

3

4 Jing Lu^{a,b,c*}, Jinju Peng^{a,b,c*}, Qianling Xiong^{a,b,c*}, Zhe Liu^{a,b}, Huifang Lin^{a,b}, Xiaohua Tan^b, Min Kang^b, Runyu

5 Yuan^{a,b}, Lilian Zeng^{a,b}, Pingping Zhou^{a,b}, Chumin Liang^{a,b}, Lina Yi^{a,b}, Louis du Plessis^d, Tie Song^b, Wenjun Ma^a,

6 Jiufeng Sun^{a,b#}, Oliver G Pybus^d, Changwen Ke^{b#}

7

8 **Affiliations:**

9 a Guangdong Provincial Institution of Public Health, Guangdong Provincial Center for Disease Control and
10 Prevention, Guangzhou, China

11 b Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China

12 c School of Public Health, Southern Medical University, Guangzhou, China

13 d Department of Zoology, University of Oxford, Oxford, UK

14

15 * These authors contributed equally.

16 Correspondent to:

17 Changwen Ke, email: kecw1965@aliyun.com; or Jiufeng Sun, email: sunjiuf@163.com.

18 Guangdong Provincial Center for Disease Control and Prevention, 160 Qunxian Rd, Dashi Town, Panyu District,

19 Guangdong Province, Guangzhou 511430, China.

20 **Abstract**

21 **Background**

22 COVID-19 pandemic is underway. Some COVID-19 cases re-tested positive for SARS-CoV-2 RNA after
23 discharge raising the public concern on their infectivity. Characterization of re-positive cases are urgently needed
24 for designing intervention strategies.

25 **Methods**

26 Clinical data were obtained through Guangdong COVID-19 surveillance network. Neutralization antibody titre
27 was determined using a microneutralization assay. Potential infectivity of clinical samples was evaluated after the
28 cell inoculation. SARS-CoV-2 RNA was detected using three different RT-PCR kits and multiplex PCR with
29 nanopore sequencing.

30 **Results**

31 Among 619 discharged COVID-19 cases, 87 were re-tested as SARS-CoV-2 positive in circumstance of social
32 isolation. All re-positive cases had mild or moderate symptoms in initial diagnosis and a younger age distribution
33 (mean, 30.4). Re-positive cases (n=59) exhibited similar neutralization antibodies (NAbs) titre distributions to
34 other COVID-19 cases (n=150) parallel-tested in this study. No infective viral strain could be obtained by culture
35 and none full-length viral genomes could be sequenced for all re-positive cases.

36 **Conclusions**

37 Re-positive SARS-CoV-2 was not caused by the secondary infection and was identified in around 14% of
38 discharged cases. A robust Nabs response and a potential virus genome degradation were detected from nearly all
39 re-positive cases suggesting a lower transmission risk, especially through a respiratory route.

40 **Keywords:** Re-positive; SARS-CoV-2; COVID-19; Neutralizing antibody; Virology

41 **Introduction**

42 Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus, severe acute respiratory syndrome
43 coronavirus 2 (SARS-CoV-2) (1), which shares a 96% genetic similarity with the most closely related bat origin
44 SARS-like virus (RaTG13) (2). As a newly emergent virus, the clinical features of SARS-CoV-2 infections were
45 largely unknown at the beginning of the outbreak but are becoming gradually clearer as a result of global clinical
46 studies (3, 4). The design of risk assessments and successful interventions for COVID-19 are dependent on how
47 well we understand the course of SARS-CoV-2 infections.

48

49 The COVID-19 pandemic is underway (5). Social measures for monitoring, controlling and treating COVID-19
50 are varied among countries. It has been suggested that the detection of antibodies to SARS-CoV-2 could serve as
51 the basis for an “immunity passport”, however it is currently unclear whether recovered COVID-19 cases have
52 neutralizing antibodies that protecting them from a second infection. There have been reports that some recovered
53 COVID-19 cases have re-tested positive for SARS-CoV-2 RNA a few days after discharge (6, 7). Since a RT-PCR
54 test that targets a short fragment of the virus genome cannot indicate if an individual is infectious or not, we define
55 in this study these observations as “re-positive” cases, not relapse or repeat infection cases.

56

57 Re-positive detection of SARS-CoV-2 RNA raises questions about the transmission risk of the disease, including,
58 (i) the percentage of re-positive in COVID-19 discharged cases and its association with clinical characters, (ii) the
59 immune status of re-positive cases, and (iii) infectivity of re-positive cases.

60

61 Guangdong Province reported the highest number of COVID-19 cases in China except Hubei. Guangdong
62 launched an enhanced surveillance network and a series of intervention measures in response to the outbreak soon
63 after the first COVID-19 case was reported in December 2019 (8). Since 23 January, all discharged COVID-19
64 cases were isolated in designated hotels under medical observation for another 14 days. In this study, we screened
65 619 recovered COVID-19 cases in Guangdong discharged between 23 January and 19 February. One hundred
66 thirty-seven swabs and 59 serum samples from 70 re-positive cases were collected in order to reveal the
67 immunological and virologic characteristics of the SARS-CoV-2 re-positive cases.

68

69 **Methods**

70 **Discharge criteria and after discharge measures for COVID-19 cases in Guangdong**

71 Guangdong follows the Diagnosis and Treatment Scheme of SARS-CoV-2 released by the National Health
72 Commission of China with a little modification. The Discharge criteria a for COVID-19 cases in Guangdong
73 include: 1) Body temperature is back to normal for more than three days; 2) Respiratory symptoms improve
74 obviously; 3) Pulmonary imaging shows obvious absorption of inflammation, and 4) Nuclei acid tests negative
75 twice consecutively on both respiratory tract samples such as sputum and nasopharyngeal swabs and digestive
76 tract samples such as stool and anal swabs (sampling interval being at least 24 hours). The interventions
77 measures for discharged COVID-19 cases include: 1) all discharged COVID-19 cases are isolated in designated
78 hotels for another 14 days; 2) during the isolation, discharged cases live in well-ventilated single room, separate
79 dining, practice hand hygiene and minimize close contact with others; 3) health status are monitored during the
80 isolation and SARS-CoV-2 RT-PCR tests are performed on 7th and 14th or more frequently after discharge; 4)

81 cases could back home only when nuclei acid tests are negative on both respiratory tract samples and digestive

82 tract samples during the isolation. The clinical outcome was categorized as mild, moderate, severe, and critical

83 as previously described (8).

84

85 **Case definition and specimen collection**

86 The term “re-positive case” in this study refers to the discharged cases who retested as SARS-CoV-2 positive
87 using real-time Reverse-Transcription Polymerase Chain Reaction (RT-PCR; see below). In Guangdong, all
88 discharged COVID-19 cases were continuously isolated in designated hotels and samples including
89 nasopharyngeal swabs, throat swabs and anal swabs, were collected for RT-PCR diagnosis at 7 days and 14 days
90 after discharge, or more frequently. The demographic, clinical and laboratory information of all confirmed
91 COVID-19 cases were retrieved from Guangdong Provincial COVID-19 surveillance network.

92

93 **Viral isolation and RT-PCR**

94 Vero E6 cells were inoculated with 100 µl processed patient sample. Cytopathic effect (CPE) were observed daily.
95 If there was no CPE observed, cell lysis was collected by centrifugation after three repeated freeze-thaw and 100
96 µl supernatant were used for the second round of passage. For RT-PCR diagnosis, total RNA was extracted from
97 clinical specimens using the QIAamp Viral RNA mini kit (QIAGEN, Germany) according to the manufacturer’s
98 instructions. In this study, 3 RT-PCR kits were used to conduct nucleic acid testing, in an attempt to avoid the
99 occurrence of false negatives. Kit A (DAAN GENE, Guangzhou, China) and Kit B (BioGerm, Shanghai, China)
100 have primers and probes targeting the open reading frame (ORF1ab) and nucleocapsid protein (N), respectively.
101 Kit C (Liferiver, Shanghai, China) is designed to detect RNA-dependent RNA polymerase (RdRp), envelope
102 protein (E) and N.

103

104 **Microneutralization assay**

105 Serum samples were collected from re-positive cases, cases in hospitalization and general discharged COVID-19
106 cases at more than 21 days post illness onset. Microneutralization antibody assays for SARS-CoV-2 were
107 performed in a BSL-3 laboratory according to the standard protocol of a neutralization test. A local SARS-CoV-2
108 strain isolated from the first COVID-19 patient in Guangdong (GISAID accession ID: EPI_ISL_403934) was
109 used microneutralization assay. All neutralizing antibody assays were run in 96-well microplates. Serum samples
110 were inactivated at 56°C for 30 mins before use, diluted two-fold from 1:4 to 1:1,024, and then incubated at 37°C
111 for 2 hours with equal volumes of 100 half tissue culture infective doses (100 TCID₅₀). Thereafter, the mixture
112 was added into 96-well Vero-E6 cell culture plate. The viral-induced CPE was monitored daily for 7 days. All the
113 diluted samples were tested in duplicate. Cell control, serum control and virus control were included in each plate.
114 Virus back titration was conducted in each test. The antibody titre of the sample was defined as the highest dilution
115 that could inhibit CPE development in 50% of the virus-infected wells.

116

117 **High-throughput sequencing**

118 For the multiplex PCR approach, we followed the general method of multiplex PCR as described in
119 (<https://artic.network/ncov-2019>) (9). Briefly, multiplex PCR was performed with two pooled primer mixtures
120 and cDNA reverse-transcribed with random primers was used as a template. After 35 rounds of amplification,
121 PCR products were collected and quantified, followed by end-repairing and barcoding ligation. Around 50 fmol of
122 final library DNA was loaded onto the MinION sequencing device. The ARTIC bioinformatics pipeline for
123 COVID (<https://artic.network/ncov-2019>) was used to generate consensus sequences and call single nucleotide
124 changes relative to the reference sequence (MN908947). Assembly of the nanopore raw data was performed using

125 the ARTIC bioinformatic pipeline for COVID-19 with minimap2 (10) and medaka
126 (<https://github.com/nanoporetech/medaka>) for consensus sequence generation. Sequencing data after mapping to
127 SARS-COV-2 reference genome (MN908947.3) have been deposited in the Genome Sequence Archive (11) in
128 BIG Data Center (12), Beijing Institute of Genomics (BIG), Chinese Academy of Sciences, under project
129 accession numbers CRA002500, publicly accessible at <https://bigd.big.ac.cn/gsa>.

130

131 **Statistical analysis**

132 Statistical analyses were completed using R version 3.5.1 and GraphPad Prism 8.0 (GraphPad Software, Inc., San
133 Diego, CA). Continuous variables that fitted a normal distribution were compared using Student's t-test and
134 analysis of variance (ANOVA) otherwise they were analysed using the Wilcoxon rank test and Kruskal-Wallis H
135 test. Categorical variables were compared using a Chi-square test or Fisher's Exact Test to assess deviation from
136 the null hypothesis. Spearman's correlation was to assess the correlation between age and Neutralization antibody
137 titre. A p -value <0.05 was determined to be statistically significant.

138

139 **Ethics Approval**

140 This study was reviewed and approved by the Medical Ethical Committee of Guangdong Provincial Center for
141 Disease Control and Prevention. Data collection and analysis of cases were determined by the Health Commission
142 of Guangdong province to be part of a continuing public health outbreak investigation during the emergency
143 response and were thus considered exempt from institutional review board approval.

144 **Results**

145 **Clinical characteristics of re-positive cases**

146 A total of 619 COVID-19 cases were discharged from designated hospitals between 23 January and 19 February,
147 2020. These cases were continuously isolated in designated hotels and were all screened for SARS-CoV-2 after
148 discharge (see details in Methods). Up to 25 February 2020, 87 cases (14%) retested as positive for SARS-CoV-2
149 RNA via RT-PCR and returned to the local designated hospital for isolation and medical observation. The
150 demographic characteristics of 87 re-positive cases are as follows: (i) the gender distribution was equal, with 45
151 males and 42 females; (ii) re-positive detection of viral RNA was observed in all age groups, ranging from 11
152 months to 68 years, with an average age of 30.4 years, which is significantly younger than that of general
153 COVID-19 patients in Guangdong (average age of 44.8 years, Table 1). Notably, all re-positive cases had only
154 mild (46) or moderate (41) clinical symptoms during initial hospitalization and first retested as SARS-CoV-2 viral
155 RNA positive at a mean of 6.7 days (range 3 to 10 days) post-discharge. Possibly due to their moderate clinical
156 symptoms, re-positive cases had shorter hospital stays (mean, 14.8 days) than general COVID-19 cases (mean,
157 20.1 days) (Table 1). After discharge, 77 of 87 re-positive cases were asymptomatic, and 10 cases had a symptom
158 of unproductive cough, mainly at night. Forty-four cases received computerized tomography (CT) examination,
159 and no abnormalities were reported.

160

161 **Neutralizing antibody in re-positive cases**

162 An impaired immune response has been associated with fatal COVID-19 infections that exhibit prolonged
163 persistence of viral RNA (13). One possible explanation for the re-positive detection of SARS-CoV-2 RNA is that

164 some COVID-19 patients may have insufficient immune responses and neutralization antibodies (NAbs) to clear
165 infection completely. To investigate the immunological and virological characteristics of re-positive COVID-19
166 cases, 70 of 87 re-positive cases were resampled by Guangdong Provincial Center for Disease Control and
167 Prevention (GDCDC) between 22 February and 1 March, 2020 including 59 serums and 137 swab samples
168 (Figure 1A). Serum samples were collected at a median of 35 days post illness onset (ranging from 23 to 47 days).
169 As a comparison, 150 serum samples from general discharged cases (n=38) and cases in hospitalization (n=112)
170 were collected with a median duration from illness onset to serum sampling of 30 days (ranging from 22 to 47
171 days) and 32 days (ranging from 22 to 45 days), respectively. The titre of viral-specific NAbs was estimated by
172 microneutralization assay, which is regarded as a gold standard for determining protective antibodies. As shown in
173 Figure 1B, 58 of 59 (98.3%) re-positive cases developed NAbs with a titre >4, ranging from 4 to >1024. Our
174 results demonstrated competent immune activation in re-positive cases, which exhibit a distribution of NAbs titres
175 similar to that of general discharged cases and COVID-19 cases in hospitalization (Kruskal-Wallis H test, $p=0.12$,
176 Figure 1B).

177

178 **Viral RNA detection and viral isolation in re-positive cases**

179 A total of 137 swabs, including 51 nasopharyngeal swabs, 18 throat swabs and 68 anal swabs, were tested using
180 three different RT-PCR kits, in an attempt to reduce the chance of false negatives caused by difference in
181 sensitivity and primer specificity. Fifty re-positive cases had paired nasopharyngeal swabs and anal swabs, and
182 18 cases had paired throat swabs and anal swabs for viral RNA detection. Thirty-six swabs from 33 cases were
183 detected as positive by at least one RT-PCR kit (Table S1). RT-PCR positive rates were not statistically different

184 for different sample types in 68 paired samples (anal swabs vs nasopharyngeal swabs, and anal swabs vs throat
185 swabs; Chi-square test, $p=0.648$; Fisher exact test, $p=0.443$). In this cross-sectional analysis, 32 of 33 cases had
186 clear information on time intervals of illness onset, discharge and sample testing (Figure 2). We find that the
187 duration from discharge to the time tested as re-positive can range from 6 to 28 days (Figure 2). Importantly,
188 there was no correlation between neutralization antibody titre and the length of time between discharge and the
189 date the case tested as re-positive. For example, for Case 21, SARS-CoV-2 RNA was re-detected at 28 days after
190 discharge and 46 days post symptom onset, yet NAb titre for this case was as high as 1024 (Figure 2). The 36
191 RT-PCR positive samples including 14 nasopharyngeal swabs, 3 throat swabs and 19 anal swabs. These RT-PCR
192 positive samples were inoculated into Vero-E6 cell line but no live viruses could be cultured following two
193 rounds of cell passage.

194

195 **Virus whole genome sequencing in re-positive cases**

196 A previously study proved virus isolation success was also depended on viral load, and samples containing $<10^6$
197 copies/mL (or copies per sample) never yielded an isolate (3). For acute infection cases, we found that high
198 quality SARS-CoV-2 genomes could be obtained by using a multiplex PCR method even for samples with a low
199 viral load (8). Therefore, the successive detection of a complete or nearly complete viral genome may provide
200 clues on the status of viral replication. None of full-length SARS-CoV-2 genome could be obtained by
201 sequencing 94 samples from 54 patients and the sequencing coverage ranged from 0.00–75.48% (Figure 3A,
202 Table S1).

203

204 Intriguingly, a discrepancy was observed between the results of RT-PCR and multiplex PCR sequencing (Figure
205 3A & B). For instance, 21 of 33 samples that were RT-PCR positive did not perform well in sequencing and
206 produced sequences that covered < 10% of the virus genome (Figure 3B). Conversely, 12 samples detected as
207 negative by three RT-PCR kits gave rise to virus sequences that spanned >10% of the virus genome (Figure 3A
208 & 3B). This discrepancy could be expected when the viral genome was not intact and the primers in RT-PCR
209 and multiplex PCR targeting the different fragments of viral genome.

210

211 Sequencing results of matched samples from individual cases (anal swabs vs nasopharyngeal swabs, and anal
212 swabs vs throat swabs) showed that the genome coverage of sequences from digestive samples were
213 significantly higher than that of the matched respiratory swabs (Figure 3C). For case 6 and case 42 having
214 sequencing results of matched samples, we observed some single nucleotide variants (SNVs) between viral
215 genome sequences achieved from respiratory samples and that from digestive samples (Figure 3A).

216

217 **Discussion**

218 Tens of thousands of people have recovered from COVID-19 infection, and there have been preliminary reports
219 of people testing re-positive for SARS-CoV-2 viral RNA after recovery [7,8]. Here, we use data from the
220 Guangdong COVID-19 surveillance system to analyse the characteristics of re-positive cases in Guangdong
221 between 23 January and 26 February, and we explore questions such as the percentage, immune status and
222 infectivity of re-positive cases.

223

224 The first question we addressed is the re-positive rate in COVID-19 discharged cases. Here, the discharge
225 criteria are according to the Diagnosis and Treatment Scheme of SARS-CoV-2 (see Methods for detail). By
226 screening 619 discharged cases, up to 25 February, the percentage of SARS-CoV-2 re-positive cases is around
227 14%. According to the scheme, all discharged cases are continuously isolated in designated hotels with strict
228 interventions on diseases transmission. Thus, the identification of re-positive SARS-CoV-2 during the isolation
229 phase exclude the possibility that re-positive cases is caused by the secondary viral infection. Our results also
230 highlight a significant feature of re-positive cases. All re-re-positive cases in our study developed only mild or
231 moderate symptoms in the initial diagnosis, with the median age significantly lower than that of the general
232 COVID-19 cases (Table 1). The relatively mild symptoms may explain why the median time from onset to
233 discharge in re-positive cases (median 19.3 days) is slightly lower than that of the other discharged COVID-19
234 cases (median 24 days). It is unlikely that cases tested as re-positive because they were discharged too early
235 since all re-positive cases tested negative for both nasopharyngeal and anal swabs in two successive tests before
236 discharge. The time from symptom onset to discharge (the time when COVID-19 cases have twice tested
237 negative by PCR) for re-positive cases (median 19.3, Table 1) is consistent with the time that detectable
238 SARS-CoV-2 RNA is reported on other studies to persist (median 20) in respiratory sites (13, 14). These data
239 indicate that the course in re-positive cases is similar to other COVID-19 cases. The re-positive of SARS-CoV-2
240 RNA is not random and mainly observed in young cases without severe clinical symptoms.

241

242 Prolonged detection of virus RNA presents a challenge to targeted public health interventions. Therefore, it is
243 important to know if re-positive cases are infectious. One previously proposed reason for prolonged detection of
244 viral RNA in deceased patients is impaired neutralizing ability (13). Our microneutralization result shows that

245 58 of 59 (98%) re-positive cases generated specific NABs to SARS-CoV-2, and their titre distribution is similar to
246 the normal recovered cases and hospitalized COVID-19 cases (Figure 1B). To investigate virus infectivity, we
247 attempted live virus isolation on different clinical samples from re-positive cases. All samples from re-positive
248 cases are diagnosed with higher CT values (Table S1) than our previous finding in acute infection cases. Due to
249 the limited sensitivity of culture method (3), infectivity may not accurately illustrated by the culture method
250 although no viral isolates were obtained from RT-PCR positive samples. Thus, we also perform the multiplex
251 PCR combined with high-throughput sequencing on these samples. The discrepancy we observed among
252 different RT-PCR kit results, as well as between RT-PCR and multiplex PCR sequencing results, suggests that
253 the virus genomes detected in re-positive cases could be highly degraded. We only recovered one virus sequence
254 with genome coverage >20% (34.5%) in 23 RT-PCR positive respiratory samples (Figure 3A). These results
255 suggest a low residual risk of infectivity of re-positive cases, especially from the respiratory transmission route.

256

257 Several limitations of our study should also be noted. First, we did not obtain successively collected samples,
258 resulting in the existence of bias toward the summarized duration from the discharge to firstly re-positive result
259 for viral RNA as well as the time of the re-positive RNA to negative. Secondly, we did not obtain the
260 corresponding samples during the acute infection for these re-positive cases. Therefore, some virologic
261 questions remain, including whether there any genetic differences for SARS-CoV-2 viruses sampled in an acute
262 infection phase and a re-positive phase. The significance of SNVs identified in different samples of re-positive
263 cases is limited by the sample size (Figure 3A) and should be further clarified in following studies.

264

265 Appropriate design intervention strategies on COVID-19 has been largely relied on how well we understand the
266 characteristics of the SARS-CoV-2 infection. Re-positive of viral RNA in some discharged cases could raise a
267 challenge for disease interventions which means a prolonged isolation phase and a more requirement on hospital
268 isolation facilities. Our study result shows a comparable Nab response in re-positive cases comparing to other
269 COVID-19 cases. More importantly, none of infective strains could be successfully isolated and no intact viral
270 genome could be sequenced from all re-positive cases samples highlighting a lower risk for disease transmission
271 from such cases. The additional educations related on SARS-CoV-2 re-positive should be performed to calm
272 down the public panic and allocate of limited medical resources.

273 **Acknowledgments**

274 We thank the laboratory and administrative personnel at Guangdong Provincial Center for Disease Control for
275 their contribution to the follow-up investigation. We also acknowledge the contributions of other clinical, public
276 health and technical staff from COVID-19 designated hospitals and city-level center for disease control and
277 prevention. This work was supported by grants from Guangdong Provincial Novel Coronavirus Scientific and
278 Technological Project (2020111107001), Science and Technology Planning Project of
279 Guangdong(2018B020207006), National Science and Technology Project(2020YFC0846800).

280 **References**

- 281 1. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y,
282 Yuan M-L, Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC,
283 Zhang Y-Z. 2020. A new coronavirus associated with human respiratory disease in
284 China. *Nature* 1–8.
- 285 2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang
286 C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang
287 X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao
288 G-F, Shi Z-L. 2020. A pneumonia outbreak associated with a new coronavirus of
289 probable bat origin. *Nature* 1–4.
- 290 3. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D,
291 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J,
292 Ehmann R, Zwirgmaier K, Drosten C, Wendtner C. 2020. Virological assessment of
293 hospitalized patients with COVID-2019. *Nature*.
- 294 4. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo
295 X, Chen Y, Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F,
296 Cowling BJ, Li F, Leung GM. 2020. Temporal dynamics in viral shedding and
297 transmissibility of COVID-19. *Nature Medicine* 1–4.
- 298 5. WHO. 2020. Coronavirus disease (COVID-2019) situation reports.

- 299 6. Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, Peng L. 2020. Recurrence of positive
300 SARS-CoV-2 RNA in COVID-19: A case report. *International Journal of Infectious*
301 *Diseases* 93:297–299.
- 302 7. Li Y, Hu Y, Yu Y, Zhang X, Li B, Wu J, Li J, Wu Y, Xia X, Tang H, Xu J. 2020. Positive
303 result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in
304 Yiwu, China. *J Med Virol*.
- 305 8. Lu J, du Plessis L, Liu Z, Hill V, Kang M, Lin H, Sun J, François S, Kraemer MUG,
306 Faria NR, McCrone JT, Peng J, Xiong Q, Yuan R, Zeng L, Zhou P, Liang C, Yi L, Liu J,
307 Xiao J, Hu J, Liu T, Ma W, Li W, Su J, Zheng H, Peng B, Fang S, Su W, Li K, Sun R,
308 Bai R, Tang X, Liang M, Quick J, Song T, Rambaut A, Loman N, Raghwani J, Pybus
309 OG, Ke C. 2020. Genomic Epidemiology of SARS-CoV-2 in Guangdong Province,
310 China. *Cell* S0092867420304864.
- 311 9. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, Oliveira G,
312 Robles-Sikisaka R, Rogers TF, Beutler NA, Burton DR, Lewis-Ximenez LL, de Jesus
313 JG, Giovanetti M, Hill SC, Black A, Bedford T, Carroll MW, Nunes M, Jr LCA, Sabino
314 EC, Baylis SA, Faria NR, Loose M, Simpson JT, Pybus OG, Andersen KG, Loman NJ.
315 2017. Multiplex PCR method for MinION and Illumina sequencing of Zika and other
316 virus genomes directly from clinical samples. *Nature Protocols* 12:1261–1276.
- 317 10. Li H. 2018. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics*
318 34:3094–3100.

- 319 11. Wang Y, Song F, Zhu J, Zhang S, Yang Y, Chen T, Tang B, Dong L, Ding N, Zhang Q,
320 Bai Z, Dong X, Chen H, Sun M, Zhai S, Sun Y, Yu L, Lan L, Xiao J, Fang X, Lei H,
321 Zhang Z, Zhao W. 2017. GSA: Genome Sequence Archive. *Genomics Proteomics
322 Bioinformatics* 15:14–18.
- 323 12. National Genomics Data Center Members and Partners. 2020. Database Resources of
324 the National Genomics Data Center in 2020. *Nucleic Acids Res* 48:D24–D33.
- 325 13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei
326 Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk
327 factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
328 retrospective cohort study. *The Lancet* 395:1054–1062.
- 329 14. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P,
330 Chan JM-C, Chik TS-H, Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip
331 JD, Ng AC-K, Poon RW-S, Luo C-T, Cheng VC-C, Chan JF-W, Hung IF-N, Chen Z,
332 Chen H, Yuen K-Y. 2020. Temporal profiles of viral load in posterior oropharyngeal
333 saliva samples and serum antibody responses during infection by SARS-CoV-2: an
334 observational cohort study. *The Lancet Infectious Diseases* 0.
- 335

Table 1. Demographic and clinical data of re-positive and normal COVID-19 cases

	Normal cases	Re-positive cases	<i>P</i> value
Demographics			
Age (average, range)	44.8 (0.8-90)	30.4 (0.9-68)	<0.001
Gender			
Male	218/425(48.7%)	45/87(51.7%)	>0.05
Female	207/425(51.3%)	42/87(48.3%)	
Clinical classification			
Mild	28/256(10.9%)	46/87(52.9%)	<0.001
Moderate	167/256(65.2%)	41/87 (47.1%)	
Severe	61/256(23.8%)	0/87(0)	
Clinical course (n=69)			
Onset-hospitalization (days)	6.7 (0-37)	3.2 (0-13)	<0.001
Hospital stay	20.1(4-32)	14.8 (6-28)	<0.01
Discharge-sampling	N/A	6.7 (3-10)	N/A
Onset-discharge	N/A	18.8 (9-37)	N/A

Onset-sampling

N/A

33.2 (19-47)


N/A

Note: N/A indicates unavailable data. Clinical data were from 69 re-positive cases since these data were incomplete among 87 re-positive cases.

336

337 **Figure legends**


338 **Figure 1.** (A) Summary of sampling scheme in this study; (B) Comparison of Nab titres among infections that
339 were re-positive, general discharged COVID-19 cases, and cases in hospitalization. General discharged cases
340 refer to COVID-19 recovered cases detected as SARS-CoV-2 negative in 14 days after discharge. To plot these
341 results into one figure, we recorded 2 for antibody titre less than 4 (highlighted in red), and 2048 for titre larger
342 than 1024. The start point of serum dilution (titre of 4) was highlighted with red dash line.



343

344




345 **Figure 2.** Timeline of 32 COVID-19 re-positive cases sampled and tested between 28 February–1 March.



346

347

348 **Figure 3.** (A) Virus genome sequences (for those samples with genome coverage >10%) obtained from
349 re-positive cases. Single nucleotide polymorphisms (with respect to the reference genome MN908947.3) are
350 coloured in red. Genome sequence fragments are coloured blue, orange to indicate whether they were obtained
351 from anal, nasopharyngeal and throat swabs, respectively. The corresponding RT-PCR results from three
352 different RT-PCR kits were shown on the right side and positive results were marked with rectangles. (B)
353 Coverage of the consensus sequence among nasopharyngeal swabs, throat swabs and anal swabs. A solid circle
354 refers a RT-PCR positive sample, and a hollow circle refers a RT-PCR negative sample. The red dash line refers
355 to the sequencing coverage of 10%; (C) Coverage of consensus sequence measured from respiratory tract
356 (nasopharyngeal swabs/throat swabs) and matched digestive tract (anal swabs).



357